Clinical Trials Logo

Clinical Trial Summary

The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane B2 inhibition.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)


Related Conditions & MeSH terms


NCT number NCT01094483
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date March 2010
Completion date May 2010

See also
  Status Clinical Trial Phase
Completed NCT01515345 - Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry Phase 3